Bayer’s oral multi-kinase inhibitor regorafenib has hit survival targets in a Phase III trial involving patients with liver cancer.
The German drugmaker didn’t reveal the specific data at this time, but said it would be presented at an upcoming medical conference and used to as a basis for filing the drug with regulators later this year.
HCC is the most common form of liver cancer and accounts for around 70-85 percent of all liver cancer cases, of which there are more than 780,000 diagnosed worldwide each year. In 2012, around 746,000 people died of the disease.
“Effective treatment options are urgently needed for patients with liver cancer,” said Dr Joerg Moeller, member of the Executive Committee of Bayer AG’s Pharmaceutical Division and head of development. “With sorafenib having been a major advance in the treatment of unresectable HCC, regorafenib could now become the second proven systemic option for the treatment of liver cancer.”
Regorafenib is already on the market under the brand name Stivarga for the treatment of metastatic colorectal cancer and metastatic gastrointestinal stromal tumors (GIST).